aficamten · Cytokinetics · NDA 219083
Myqorzo
Earliest generic entry, as listed · earliest of 4 marketed strengths
15 Jul 2042
Blocked by patent: US 12370179. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12370179 | use U-4371 | 15 Jul 2042 |
| US 10836755 | substance, product, use U-4371 | 18 Jan 2039 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 19 Dec 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219083 · 001 · RLD | tablet, oral | 5MG | 15 Jul 2042 |
| 219083 · 002 · RLD | tablet, oral | 10MG | 15 Jul 2042 |
| 219083 · 003 · RLD | tablet, oral | 15MG | 15 Jul 2042 |
| 219083 · 004 · RLD | tablet, oral | 20MG | 15 Jul 2042 |